Privia Health to Acquire Evolent’s ACO Business Unit for $100M

Physician enablement company Privia Health Group plans to acquire Evolent Health’s accountable care organization (ACO) business, a move that will significantly expand its value-based care (VBC) footprint.  

The transaction provides Privia with strategic growth opportunities. It will gain Evolent Care Partners’ 120,000 attributed lives in the Medicare Shared Savings Program (MSSP)—which represents a significant earnings contributor for Privia—along with various commercial and Medicare Advantage (MA) programs. This will increase the company’s total reach to about 1.5 million attributed lives across commercial, Medicare, MA, and Medicaid.  

Other strategic benefits for Privia include the following: 

• Geographic expansion. Deepening Privia’s VBC presence in existing states and adding attributed lives in 11 new states.
• Synergy opportunities. Evolent’s ACO-participating providers can join Privia’s medical groups, gaining access to Privia’s full suite of services and technology platform. 
• Continued growth. The acquisition positions Privia for positive financial performance in the coming years.

Evolent Health provides care management and health plan administrative solutions for payers to manage high-cost specialty care. Evolent Care Partners collaborates with more than 1,000 physicians. The divestiture enables sharper focus on specialty condition management, including oncology, cardiology, and musculoskeletal care.  

Financially, Privia will pay $100 million in cash up front and up to $13 million subject to final MSSP performance for 2025. The transaction is expected to close in Q4 2025 and positively contribute to adjusted EBITDA in 2026. Privia will finance the transaction with cash on its balance sheet. 

Privia, which went public in 2021, is one of the biggest physician enablement companies in the U.S., with a footprint in 15 states and Washington, D.C.The firm works with more than 4,500 providers to help medical groups, hospitals, and other organizations implement value-based care arrangements with financial payouts tied to patient outcomes, care quality, and other metrics instead of being based on the volume or complexity of services. 

Evolent CEO Seth Blackley said the company’s proceeds will be used to repay senior credit facility borrowings, reducing leverage and improving annual cash flow by more than $7 million. Offloading its ACO business will also allow Evolent to refocus on its core specialty care management business.

The Deal’s Financial Breakdown

As we’ve previously reported, Privia has already demonstrated strong MSSP cost and quality performance, and its acquisition of Evolent Health’s ACO business aligns more closely with Privia’s focus on primary care and risk management.

Meanwhile, Evolent now can concentrate on specialty care, which has always been its differentiator.  

Overall, analysts agree that the deal strengthens Privia’s VBC scale and financial profile, while allowing Evolent to sharpen its strategic focus and improve cash flow. 

Evolent reaffirmed its Q3 outlook of $460 million to $480 million in revenue and $34 million to $42 million in adjusted EBITDA, with full-year guidance at $1.85 billion to $1.88 billion in revenue and $140 million to $165 million in adjusted EBITDA.

Healthcare Innovation staff members may occasionally use AI tools to assist with content. Elements of this article were created with help from OpenAI's GPT5.